COST-UTILITY ANALYSIS OF DELAYED-RELEASE DIMETHYL FUMERATE FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN PORTUGAL

被引：2
|
作者：
Silva Miguel, L. [1 ]
de Sa, J. [2 ]
Pinheiro, B. [1 ]
Acosta, C. [3 ]
机构：
[1] CISEP Res Ctr Portuguese Econ, Lisbon, Portugal
[2] Ctr Hosp Lisboa, Lisbon, Portugal
[3] Biogen Idec Inc, Lisbon, Portugal
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.2471
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PND56
引用
收藏
页码：A758 / A758
页数：1
相关论文
共 50 条
  • [31] Cost-utility analysis of alemtuzumab in comparison with interferon beta, fingolimod, and natalizumab treatment for relapsing-remitting multiple sclerosis in Austria
    Walter, Evelyn
    Berger, Thomas
    Bajer-Kornek, Barbara
    Deisenhammer, Florian
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (03) : 226 - 237
  • [32] Absolute Lymphocyte Count in Patients with Relapsing-Remitting Multiple Sclerosis Treated with Delayed-release Dimethyl Fumarate: Considerations for Patient Management
    Fox, Robert
    Chan, Andrew
    Gold, Ralf
    Phillips, J. Theodore
    Yang, Lili
    Liu, Shifang
    Prada, Claudia
    Ray, Soma
    Mehta, Devangi
    Taylor, Catherine
    Fay, Monica
    NEUROLOGY, 2017, 88
  • [33] COST-EFFECTIVENESS ANALYSIS OF DIMETHYL FUMARATE IN THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN ITALY
    Mantovani, L. G.
    Furneri, G.
    Cortesi, P. A.
    Puma, E.
    Santoni, L.
    Prosperini, L.
    VALUE IN HEALTH, 2019, 22 : S740 - S741
  • [34] Dimethyl fumarate in the treatment of relapsing-remitting multiple sclerosis: an overview
    Bomprezzi, Roberto
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2015, 8 (01) : 20 - 30
  • [35] COMPARATIVE EFFECTIVENESS USING A MATCHING-ADJUSTED INDIRECT COMPARISON BETWEEN DELAYED-RELEASE DIMETHYL FUMARATE AND FINGOLIMOD FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS
    Fox, R. J.
    Cutter, G.
    Chan, A.
    Xiao, J.
    Okwuokenye, M.
    Levison, D.
    Lewin, J.
    Edwards, M. R.
    Marantz, J. L.
    VALUE IN HEALTH, 2015, 18 (07) : A750 - A750
  • [36] Delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis - findings from a real-world setting in Russian Federation
    Davydovskaya, M.
    Pozhidaeva, N.
    Dubchenko, E.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 934 - 935
  • [37] Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of relapsing-remitting multiple sclerosis
    Fox, R. J.
    Cutter, G.
    Chan, A.
    Xiao, J.
    Okwuokenye, M.
    Levison, D.
    Lewin, J. B.
    Edwards, M. R.
    Marantz, J. L.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 530 - 531
  • [38] Delayed-release Dimethyl Fumarate Demonstrates Sustained Efficacy over Nine Years in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis
    Gold, Ralf
    Giovannoni, Gavin
    Phillips, J. Theodore
    Bar-Or, Amit
    Fox, Robert J.
    Chen, Chongshu
    Miller, Catherine
    NEUROLOGY, 2019, 92 (15)
  • [39] Safety of Delayed-release Dimethyl Fumarate in Relapsing-Remitting Multiple Sclerosis Patients from ENDORSE: Seven-Year Interim Results
    Pozzilli, Carlo
    Phillips, J. Theodore
    Fox, Robert J.
    Prada, Claudia
    Yang, Lili
    Taylor, Catherine
    Fay, Monica
    NEUROLOGY, 2017, 88
  • [40] Delayed-release dimethyl fumarate demonstrates sustained efficacy over nine years in newly diagnosed patients with relapsing-remitting multiple sclerosis
    Gold, R.
    Giovannoni, G.
    Phillips, J. T.
    Bar-Or, A.
    Fox, R. J.
    Chen, C.
    Miller, C.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 498 - 499
12345